The role and significance of non-invasive DNA testing

Non-invasive DNA testing (NIPT) is an advanced prenatal screening technology that collects maternal peripheral blood and analyzes fetal cell-free DNA. It is mainly used to assess the risk of fetal chromosomal abnormalities, such as Down syndrome (T21), Edwards syndrome (T18), etc. Its core advantage lies inSafe, accurate and early, avoiding the risk of miscarriage caused by traditional amniocentesis. The test can also help determine the gender of the fetus and some microdeletion syndromes. The content will focus on its clinical value, applicable population, technical principles and limitations, and will be accompanied by relevant data and product information.

1. Core functions of non-invasive DNA testing

Non-invasive DNA testing uses high-throughput sequencing technology to analyze fetal cell-free DNA fragments in maternal blood, mainly targetingChromosomal aneuploidy diseasesGet screened. Taking Down syndrome as an example, the detection rate can reach 99%, and the false positive rate is less than 0.1% (data source: 2021 Guidelines of "Chinese Journal of Obstetrics and Gynecology"). In addition, some high-end tests can also cover sex chromosome abnormalities (such as Turner syndrome) and microdeletions/duplications above 1Mb. This technology is suitable for pregnant women over 12 weeks of pregnancy, especially for those with advanced age (≥35 years old), ultrasound abnormalities, or high-risk groups for serological screening.

2. Technical advantages and applicable scenarios

Compared with traditional amniocentesis, non-invasive DNA testingZero risk of miscarriage, and can be performed at 10 weeks of pregnancy, shortening the waiting period. Clinical studies show (quoted from the American College of Obstetricians and Gynecologists ACOG guidelines) that its negative predictive value for T21 exceeds 99.9%, which greatly reduces the psychological burden on pregnant women. However, it should be noted that this technology still belongs to the scope of screening, and the confirmed diagnosis needs to be combined with invasive diagnosis. For special groups such as obese (BMI ≥ 40), pregnant women with multiple gestations, or those who have received blood transfusions, the detection accuracy may be affected.

3. Common products and selection suggestions in the market

When choosing, you need to pay attention to the laboratory qualifications (such as CAP certification), testing cycle (usually 5-10 working days) and report interpretation services. Some products are extended to rare disease screening, but doctors are required to evaluate the necessity.

4. Summary and matters needing attention

Non-invasive DNA testing has revolutionized prenatal screening, but itsNot a substitute for diagnostic testing. Pregnant women should combine ultrasound, medical history and other comprehensive assessments to avoid over-reliance on a single result. The current domestic price ranges from 1,500 to 3,000 yuan, and medical insurance reimbursement policies vary from place to place. In the future, as technology advances, the scope of testing may be further expanded, but ethical issues (such as non-medical gender identification) still require strict supervision.

Quote sources:
1. "Chinese Medical Association Prenatal Screening Technical Guidelines (2021 Edition)"
2. US ACOG Practice Bulletin No. 226 (2020)
3. BGI official website product instructions
4. Berry and Kang clinical validation data (2019)